Rapid development of tolerance to sub-anaesthetic dose of ketamine: An oculomotor study in macaque monkeys

Psychopharmacology

Volumn 209, Issue 4, 2010, Pages 313-318

  Pouget, Pierre ^a,b   Wattiez, Nicolas ^a,b   Rivaud Péchoux, Sophie ^a,b   Gaymard, Bertrand ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antisaccade; Ketamine; Monkey; Neuropharmacology; Schizophrenia; Tolerance

Indexed keywords

KETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; EYE MOVEMENT CONTROL; FEMALE; LATENT PERIOD; MACACA; MALE; NEUROPHARMACOLOGY; NONHUMAN; POST HOC ANALYSIS; PRIORITY JOURNAL; SACCADIC EYE MOVEMENT; SCHIZOPHRENIA; TASK PERFORMANCE;

ANESTHETICS, DISSOCIATIVE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HALLUCINOGENS; INJECTIONS, INTRAMUSCULAR; KETAMINE; MACACA; MALE; NYSTAGMUS, PATHOLOGIC; REACTION TIME; SACCADES; SCHIZOPHRENIA; TIME FACTORS;

EID: 77953287576     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1797-8     Document Type: Article

References (19)

1. Amemori T, Bures J (1990) Ketamine blockade of spreading depression: rapid development of tolerance. Brain Res 519:351-354 (Pubitemid 20199711)
2. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methylaspartate. Br J Pharmacol 79:565-575
3. Bree MM, Feller I, Corssen G (1967) Safety and tolerance of repeated anesthesia with CI 581 (Ketamine) in monkeys. Anesth Analg 46:596-600
4. Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C (2008) Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 32:1014-1023
5. Condy C, Wattiez N, Rivaud-Péchoux S, Gaymard B (2005) Ketamine-induced distractibility: an oculomotor study in monkeys. Biol Psychiatry 57:366-372
6. Gilmour G, Pioli EY, Dix SL, Smith JW, Conway MW, Jones WT et al (2009) Diverse and offen opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacology 205:203-216
7. Godaux E, Cheron G, Mettens P (1990) Ketamine induces failure of the oculomotor neural integrator in the cat. Neurosci Lett 116:162-167
8. Gunduz-Bruce H (2009) The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 60:279-286
9. Kalkman CJ, Drummond JC, Patel PM, Sano T, Chesnut RM (1994) Effects of droperidol, pentobarbital, and ketamine on myogenic transcranial magnetic motor-evoked responses in humans. Neurosurgery 35:1066-1071 (Pubitemid 24371192)
10. Lahti AC, Koffel B, LaPorte D, Tamminga CA. (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
11. Livingston A, Waterman AE (1978) The urinary excretion of ketamine and its metabolites in the rat. Br J Pharmacol 64:402P
12. Morgan CJ, Huddy V, Lipton M, Curran HV, Joyce EM (2009) Is persistent ketamine use a valid model of the cognitive and oculomotor deficits in schizophrenia? Biol Psychiatry 65:1099-1102
13. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV (2008) Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend 95:219-229
14. Orser BA, Pennefather PS, MacDonald JF (1997) Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 86:903-917
15. Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byrne PP (1998) Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19:434-444
16. Sinner B, Graf BM (2008) Ketamine, in handbook. Exp Pharmacol 182:313-333
17. Stefanovic A, Brandner B, Klaassen E, Cregg R, Nagaratnam M, Bromley LM et al (2009) Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia? J Clin Psychopharmacol 29:124-133
18. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR (2007) Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33:69-94
19. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, Iga T (2001) Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 29:887-890 (Pubitemid 32488646)